• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Nurix Therapeutics Inc.

    11/3/25 4:27:15 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NRIX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001817217
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    NURIX THERAPEUTICS INC
    SEC File Number
    001-39398
    Address of Issuer
    1700 Owens Street, Suite 205
    San Francisco
    CALIFORNIA
    94158
    Phone
    4156605320
    Name of Person for Whose Account the Securities are To Be Sold
    JOHANNES VAN HOUTE
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    628481314.967688343611/03/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common10/30/2025Restricted Stock UnitsIssuerCheckbox not checked628410/30/2025N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    JOHANNES VAN HOUTE
    1700 Owens Street, Suite 205
    San Francisco � CA � 94158
    Common10/30/2025313040053.67

    144: Remarks and Signature

    Remarks
    Date of Notice
    11/03/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/12/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Johannes van Houte

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $NRIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRIX

    DatePrice TargetRatingAnalyst
    11/24/2025$30.00Buy
    Truist
    10/21/2025$24.00Outperform
    Mizuho
    3/17/2025$16.00Market Perform
    Leerink Partners
    12/10/2024$35.00Buy
    BTIG Research
    12/6/2024$35.00Outperform
    BMO Capital Markets
    10/24/2024$35.00Buy
    UBS
    10/11/2024$41.00Buy
    Jefferies
    9/6/2024$26.00Outperform
    Robert W. Baird
    More analyst ratings

    $NRIX
    SEC Filings

    View All

    Nurix Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)

    12/9/25 6:05:19 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)

    11/10/25 7:15:02 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.

    SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/7/25 11:13:45 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist resumed coverage on Nurix Therapeutics with a new price target

    Truist resumed coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $30.00

    11/24/25 9:17:24 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Nurix Therapeutics with a new price target

    Mizuho initiated coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $24.00

    10/21/25 7:21:21 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Nurix Therapeutics with a new price target

    Leerink Partners initiated coverage of Nurix Therapeutics with a rating of Market Perform and set a new price target of $16.00

    3/17/25 7:40:03 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $NRIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Chief Legal Officer Ring Christine sold $641,697 worth of shares (37,600 units at $17.07) and exercised 37,600 shares at a strike of $1.86 (SEC Form 4)

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    11/24/25 6:06:28 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Dansey Roger D

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    11/10/25 7:19:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Dansey Roger D

    3 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    11/10/25 7:18:09 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

    Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median duration of response (DOR) and median progression-free survival (PFS) have not been reached Encouraging efficacy and favorable tolerability support continued development of bexobrutideg in Waldenström macroglobulinemia Nurix will host a webcast to discuss the data presented at the ASH Annual Meeting and provide a corporate update today at 8:15 p.m. ET BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focuse

    12/8/25 8:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

    Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized Phase 1b cohorts points to higher ORR and longer progression free survival at the 600 mg recommended Phase 2 dose (RP2D) compared to the 200 mg dose Bexobrutideg was well tolerated with a consistent safety profile between the 600 mg RP2D and the overall study population Phase 2 clinical trial of bexobrutideg (DAYBreak-CLL-201) currently enrolling globally Company will host a webcast to discuss the data on Monday, December 8, 2025, at 8:15 p.m. ET BRISBANE, Calif., Dec. 06

    12/6/25 9:30:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

    SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced that the company will host a live webcast on Monday, December 8, 2025, at 8:15 p.m. ET, to review new and updated clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton's tyrosine kinase (BTK) degrader program, bexobrutideg (NX-5948), and provide a corporate update. The webcast will feature a presentation by guest speaker and clinical study investigator Alvaro Alencar, M.D., Associate Profe

    12/1/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Financials

    Live finance-specific insights

    View All

    Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

    600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bexobrutideg as potential best-in-class BTK degrader profile Nurix will host an investor webcast today, Wednesday, October 22nd, at 8:00 a.m. EDT SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced t

    10/22/25 6:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

    Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforces Nurix's scientific leadership and platform strength in targeted protein degradation Nurix remains on track to initiate pivotal trials of bexobrutideg in 2025 Data are being presented at the 30th European Hematology Association Congress (EHA2025) Company will host a webcast conference call today, June 12, 2025, at 8:00 a.m. ET (2:00 p.m. CEST) SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clin

    6/12/25 6:59:59 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

    SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the company will host a webcast conference call at 8:00 a.m., ET, on Thursday, June 12, 2025, to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association Congress in Milan, Italy. Details of the webcast and conference call are as follows: Date and time: Thursday, June 12, 8:00 a.m. ET / 2:00 p.m. CEST Access details: The live webcast will be a

    6/6/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Leadership Updates

    Live Leadership Updates

    View All

    Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

    SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization. "Roger

    11/10/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

    NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medi

    4/8/25 4:00:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

    SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today the appointment of Roy D. Baynes, MB.Bch., M.Med., Ph.D., to its board of directors. Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies. "Roy has been a trusted advisor to Nurix since 2023, and I am delighted to welcome him to our board

    3/13/25 4:00:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 9:00:57 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 4:21:48 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 4:08:39 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care